FDA Approves Opioid Analgesic for Breakthrough Cancer Pain

The Federal Drug Administration has approved the opioid analgesic Abstral tablet for breakthrough pain treatment in cancer patients, according to a Drug Watch report.

According to the report, Abstral is absorbed through mucous membranes of the mouth, gums and tongue to provide fast relief during a sudden attack of pain. The medication and other like drugs may only be prescribed to opioid-tolerate patients who are already taking opioid pain medications on a regular basis to control cancer pain.

The transmucosal tablets are available to adult patients ages 18 years or older and are administered as a quick-dissolving tablet placed under the tongue. According to the FDA's Office of New Drugs in the Center for Drug Evaluation and Research, the tablet is an important step for patients with cancer pain to have options for breakthrough pain treatment.

Read the Drug Watch report on Abstral.

Drug Dangers aims to educate and inform the public about defective medical devices and dangerous medications on the market. Learn more about Drug Dangers here: DrugDangers.com.

Read more on pain management:

-Chicago Growth Partners Acquires Advanced Pain Management

-FDA Puts Hold on Experimental Pain Drug

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers

Featured Podcast